Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pyrazinamide
Drug ID BADD_D01880
Description A pyrazine that is used therapeutically as an antitubercular agent.
Indications and Usage For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
Marketing Status approved; investigational
ATC Code J04AK01
DrugBank ID DB00339
KEGG ID D00144
MeSH ID D011718
PubChem ID 1046
TTD Drug ID D0XF8W
NDC Product Code 66639-165; 11712-815; 61748-012; 70954-484; 50090-0520; 70518-3661; 70518-2534; 50090-5963; 33342-447
UNII 2KNI5N06TI
Synonyms Pyrazinamide | Tisamid
Chemical Information
Molecular Formula C5H5N3O
CAS Registry Number 98-96-4
SMILES C1=CN=C(C=N1)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peptic ulcer07.04.07.001--Not Available
Photosensitivity reaction23.03.09.003--
Polyuria20.02.03.0020.001540%Not Available
Porphyria14.14.01.001; 03.08.01.001--Not Available
Pruritus23.03.12.0010.001540%
Pyrexia08.05.02.0030.004108%
Rash23.03.13.0010.002567%Not Available
Rash maculo-papular23.03.13.0040.002259%
Rhabdomyolysis15.05.05.0020.001027%
Seizure17.12.03.0010.001027%
Sense of oppression08.01.09.0200.001027%Not Available
Sideroblastic anaemia01.03.02.009--Not Available
Splenomegaly01.09.02.001--Not Available
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.0140.001027%
Syncope24.06.02.012; 17.02.04.008; 02.11.04.0150.001027%
Thrombocytopenia01.08.01.0020.002567%Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.0030.004621%
Tubulointerstitial nephritis20.05.02.0020.001027%Not Available
Paradoxical drug reaction08.06.01.0140.003081%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Red blood cell vacuolisation01.07.02.007--Not Available
Malnutrition14.03.02.0040.001027%Not Available
Porphyrin metabolism disorder14.14.01.006; 09.01.10.004; 03.08.01.006--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.001027%
Ill-defined disorder08.01.03.049--Not Available
Drug intolerance08.06.01.0130.001027%Not Available
Acute kidney injury20.01.03.0160.003081%
Acute yellow liver atrophy09.01.07.026--Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.009243%Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages